Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Par Pharmaceutical, Inc.
With
PRA Health Sciences
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Stage II, III,or IV lung or pancreatic cancer
Fair, poor, or very poor appetite
Cancer associated anorexia/cachexia
Weight loss perceived to be associated with diminished appetite
Eastern Cooperative Oncology Group Performance score of 0, 1, 2
Life expectancy \>3 months
Alert and mentally competent
Women of child-bearing potential required to use an adequate and reliable method of contraception. Post-menopausal women have to have been so for at least 1 year
Screening laboratory values must not be clinically significant (some exceptions per protocol)
You may not be if
Brain, or head and neck metastases that may interfere with food consumption
AIDS-related wasting
Radiation therapy to the head and neck, abdomen, or pelvis within past 6 weeks, or anticipated during course of the study such that the result may interfere with food consumption
Conditions that interfere with oral intake, or ability to swallow
Absence of a normally functioning gut
Mechanical obstruction of the alimentary or biliary tract, or malabsorption syndrome
Intractable or frequent vomiting that regularly interfere with eating
Clinically significant diarrhea
History of recurrent thromboembolic events, a thromboembolic event in past 3 months, or long-term anticoagulation treatment for thromboembolism
Uncontrolled diabetes mellitus, or symptomatic hypoadrenalism
Poorly controlled hypertension, or congestive heart failure
Pregnant/lactating females
Use within past 30 days of an appetite stimulant
Use within past week, or planned use during the study of parenteral nutrition or tube feedings
Chronic use of steroids within past 3 months (intermittent short-term use allowed)
Current use of or not willing to abstain from using illicit substances
Allergy, hypersensitivity, or contraindication to megestrol acetate
